Single Subcutaneous Dose Rising Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0349 [obesity therapies] in Overweight/Obese Male Subjects.

Trial Profile

Single Subcutaneous Dose Rising Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0349 [obesity therapies] in Overweight/Obese Male Subjects.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2012

At a glance

  • Drugs NNC 0070-0002-0349 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Oct 2008 Planned end date changed from 1 Nov 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top